— All dosing regimens were well-tolerated across the Phase 1 clinical study —

— High local exposure to AGMB-129 in the ileum —

— No clinically relevant systemic exposure to AGMB-129, confirming GI-tract targeted exposure —

Agomab Therapeutics NV (‘Agomab’) today announced positive clinical results from its Phase 1 study evaluating AGMB-129, an oral gastro-intestinal (GI)-restricted small molecule kinase inhibitor of ALK5 (TGFβRI or ALK5), intended for the treatment of Fibrostenosing Crohn’s Disease (FSCD). The trial, designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of AGMB-129 in healthy subjects, demonstrated high local exposure to AGMB-129 in the ileum and no clinically relevant systemic exposure.

The Phase 1 study included single ascending dose (SAD), multiple ascending dose (MAD) and food-effect (FE) stages, as well as an additional stage for the assessment of local drug exposure in ileal mucosa, where the fibrostenotic strictures in FSCD patients are most often located. A total of 81 healthy subjects were randomized to receive either single or multiple daily oral doses of AGMB-129, or matching placebo.

AGMB-129 was well-tolerated at all doses tested. The incidence and intensity of adverse events were similar across all dose cohorts including the placebo cohort. No drug-related safety signal or dose-limiting toxicities were identified. The favorable safety profile from the Phase 1 study supports the evaluation of AGMB-129 in a planned global Phase 2a study in patients with FSCD. Plasma PK analyses showed no clinically relevant systemic exposure, whereas biopsies of the ileum showed high local concentrations of AGMB-129, confirming that the GI-restriction mechanism can operate efficiently in humans.

“The positive results of this Phase 1 study are an important first step in our clinical development of AGMB-129 and confirm its tolerability and GI-restricted mechanism,” said Philippe Wiesel, Chief Medical Officer at Agomab Therapeutics. “We look forward to advancing AGMB-129 into a global Phase 2a study in patients with Fibrostenosing Crohn’s Disease, a disease for which there are currently no medicinal products available.”

About AGMB-129
AGMB-129 is an oral, small molecule GI-restricted inhibitor of ALK-5 (or TGFβR1) for the treatment of Fibrostenosing Crohn’s Disease (FSCD). TGFβ is a known master regulator of fibrosis and preliminary clinical data supports targeting the pathway in fibrotic indications. AGMB-129 is specifically designed to inhibit ALK5 in the GI-tract. Rapid first-pass metabolism in the liver prevents clinically relevant systemic exposure, delivering an improved safety profile over other inhibitors in its class. Fibrostenotic complications occur in up to 50% of Crohn’s disease patients and are the leading cause of bowel resection surgery. Yet, there are no approved specific therapies for FSCD.

About Agomab
Agomab is translating a deep expertise in growth factor biology to pioneer and develop novel treatments that aim to resolve fibrosis, repair tissue structure and restore organ function. Combining new scientific insights with robust drug development and a long-term corporate vision, we are building a broad clinical pipeline of differentiated programs with disease modifying potential in fibrotic diseases.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230202005442/en/

Partager sur :

d'autres actualités andera Life Sciences





ANDERA PARTNERS attire votre attention sur les tentatives de fraudes avec usurpation d’identité qui sévissent actuellement. Les techniques de phishing (ou hameçonnage) évoluent en permanence et sont de plus en plus sophistiquées.

Ces pratiques frauduleuses qui touchent ANDERA PARTNERS, invitent les particuliers à investir dans des comptes à terme et autres produits d’épargne fictifs sous l’identité d’ ANDERA PARTNERS (Andera Co-Invest notamment), et celles de ses collaborateurs et membres des organes de direction, via une adresse fictive et des appels téléphoniques.

Nous vous invitons à la plus grande vigilance si vous receviez ce type de sollicitations. ANDERA PARTNERS ne propose pas de compte à terme et n’a recours à aucun démarchage auprès du public, ni par téléphone ni par courriel.

Les fraudeurs ne manquent pas d'imagination pour piéger leurs victimes. Leurs actions visent à récupérer à leur insu et de manière indue des données financières, en incitant leurs victimes à réaliser des transactions dématérialisées.
En cas de doute, pour vous protéger et protéger ANDERA PARTNERS, nous vous invitons à :

*   Vous méfier des demandes inattendues, même si elles semblent provenir de dirigeants ou membre d’organes de direction d’ANDERA PARTNERS ;

*   Vérifier l’adresse de l’expéditeur. Les adresses électroniques des collaborateurs d’ANDERA PARTNERS utilisent un seul et même format : initialeduprénom.nom@anderapartners.com. Les adresses globales sont ainsi libellées : nomduservice@anderapartners.com ;

*   Ne jamais cliquer sur un lien vous demandant de partager des informations sensibles et ne jamais répondre à des demandes financières en ligne ;

*   Signaler tout message suspect qui vous demande une action immédiate.

La priorité d'ANDERA PARTNERS est de protéger ses clients et ses activités contre la fraude.
Si vous êtes victime d'une tentative d’escroquerie, veuillez contacter les relations investisseurs à l’adresse suivante : ri@anderapartners.com

Liens utiles :

LISTE NOIRE DES SOCIÉTÉS FRAUDULEUSES ÉTABLIE PAR L’AMF (AUTORITÉ DES MARCHÉS FINANCIERS) : https://www.amf-france.org/fr/espace-epargnants/proteger-son-epargne/listes-noires-et-mises-en-garde

VICTIME D'UNE ARNAQUE : COMMENT DÉPOSER UNE PLAINTE ? | AMF (AMF-FRANCE.ORG) : https://www.amf-france.org/fr/espace-epargnants/savoir-bien-investir/conseils-pratiques/en-cas-de-problemes/victime-dune-arnaque


ANDERA PARTNERS would like to draw your attention to fraud attempts involving identity theft that are currently rife. Phishing techniques are constantly evolving and becoming increasingly sophisticated.

These fraudulent practices, which affect ANDERA PARTNERS, invite individuals to invest in term accounts and other fictitious savings products under the identity of ANDERA PARTNERS (Andera Co-Invest in particular), and those of its employees and members of the management company, via a fictitious address and telephone calls.

Please be extremely vigilant if you receive this type of solicitation. ANDERA PARTNERS does not offer term accounts and does not canvass the public by telephone or e-mail.

Fraudsters do not lack imagination to trap their victims. Their actions are aimed at unknowingly and improperly recovering financial data, by encouraging their victims to carry out dematerialised transactions.
If in doubt, to protect yourself and ANDERA PARTNERS, we invite you to :

* Be wary of unexpected requests, even if they appear to come from ANDERA PARTNERS managers or members of management bodies;

* Check the sender's address. The e-mail addresses of ANDERA PARTNERS employees use a single format: initialeduprénom.nom@anderapartners.com. Global addresses are written as follows: nomduservice@anderapartners.com ;

* Never click on a link asking you to share confidential information and never respond to online financial requests;

* Report any suspicious message that asks you to take immediate action.

ANDERA PARTNERS' priority is to protect its customers and its business against fraud.
If you are the victim of a fraud attempt, please contact Investor Relations at the following address: ri@anderapartners.com

Ceci fermera dans 0 secondes